Form 4: Penumbra Director Surbhi Sarna Receives Equity Grant

Penumbra Inc. Director Surbhi Sarna reported the acquisition of 589 common stock units as part of an equity compensation plan.

Summary

• Surbhi Sarna, a Director of Penumbra Inc. (PEN), acquired 589 shares of common stock in the form of Restricted Stock Units (RSUs) on February 13, 2026.
• The acquisition price for these RSUs was $0 per share, which is typical for equity compensation grants.
• Following this transaction, Surbhi Sarna beneficially owns 4,293 shares of Penumbra common stock, a portion of which remains subject to vesting.
• The RSUs are scheduled to vest in four equal installments (1/4 each) on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, contingent on Ms. Sarna's continued service as a director.
• An accelerated vesting clause states that any unvested RSUs will fully vest upon the 'Closing' of the merger agreement dated January 14, 2026, between Penumbra Inc., Boston Scientific Corporation, and Pinehurst Merger Sub, Inc., also subject to continued service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard director compensation practices that align Surbhi Sarna's interests with Penumbra's long-term performance and potential strategic events.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns their financial interests with those of the shareholders, promoting long-term value creation.
• The potential for accelerated vesting upon the closing of the merger with Boston Scientific Corporation provides an additional incentive and potential benefit for the director.

Negatives

• The acquired shares are Restricted Stock Units, meaning they are not immediately liquid and are subject to vesting conditions, primarily continued service.
• The transaction does not involve an immediate cash investment by the director, which some investors might view as a less direct show of confidence compared to open market purchases.

Risks

• Vesting of the RSUs is contingent upon Ms. Sarna's continued service as a director through the specified vesting dates.
• The accelerated vesting is dependent on the 'Closing' of the merger with Boston Scientific Corporation, which introduces a contingency related to the successful completion of that transaction.

Future Outlook

The future outlook for these shares is tied to Ms. Sarna's continued service as a director through the specified vesting dates in 2026. Additionally, the potential closing of the merger with Boston Scientific Corporation could accelerate the vesting of any remaining unvested RSUs.

Industry Context

StockSavvy.ai notes that equity grants to directors, such as Restricted Stock Units, are a common practice in the medical device industry to align leadership incentives with shareholder value. Companies like Penumbra, operating in competitive healthcare technology sectors, frequently use such compensation structures to retain talent and encourage long-term strategic focus. The mention of Boston Scientific Corporation suggests ongoing strategic activity or potential consolidation within the broader medical technology landscape.

Comparison to Industry Standards

• Equity compensation in the form of Restricted Stock Units (RSUs) for non-employee directors is a standard practice across the medical device and broader technology industries. Companies such as Medtronic, Stryker, and Intuitive Surgical commonly utilize RSU grants to align director interests with long-term shareholder value.
• The vesting schedule, typically over several quarters or years, is also consistent with industry norms designed to incentivize continued service and performance.
• The inclusion of an accelerated vesting clause tied to a change of control event, such as a merger, is a common provision in RSU agreements, providing protection and incentive for directors during strategic transactions.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial incentives with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: While not directly impacting employees, the director's compensation structure reflects broader corporate governance and compensation philosophies.

Next Steps

• Vesting of 1/4 of the RSUs on March 31, 2026, subject to continued service.
• Vesting of 1/4 of the RSUs on June 30, 2026, subject to continued service.
• Vesting of 1/4 of the RSUs on September 30, 2026, subject to continued service.
• Vesting of 1/4 of the RSUs on December 31, 2026, subject to continued service.
• Potential full vesting of unvested RSUs upon the 'Closing' of the merger with Boston Scientific Corporation, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice. It does not present new information that would significantly alter the investment thesis for Penumbra Inc., thus a 'hold' recommendation is appropriate as it maintains the status quo regarding insider ownership incentives.

Keywords

Penumbra, PEN, Surbhi Sarna, Form 4, insider transaction, Restricted Stock Units, RSU, equity compensation, director, beneficial ownership, Boston Scientific, merger